News from helsinn healthcare sa A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Apr 01, 2014, 08:22 ET Medicina e tecnologia: Helsinn promuove l'uso delle tecnologie mobili nelle terapie di supporto alle cure oncologiche attraverso il mobile health

 Il gruppo farmaceutico ticinese, attore importante nelle terapie di supporto oncologico, promuove un convegno internazionale dedicato...


Mar 13, 2014, 09:00 ET Helsinn Named as One of the Best Places to Work in New Jersey by NJBIZ

Helsinn Group, the company focused on building quality cancer care, is pleased to announce today that its U.S. subsidiary, Helsinn Therapeutics...


Dec 20, 2013, 02:27 ET Helsinn e Italfarmaco rafforzano la loro alleanza attraverso la concessione dei diritti per Anamorelin, agonista del recettore grelinico in fase III, in Italia

Il gruppo Helsinn concede i diritti esclusivi di licenza e distribuzione a Italfarmaco per la commercializzazione del suo prodotto, attualmente in...


Dec 19, 2013, 02:00 ET Swiss-based Helsinn Group and Mundipharma Sign for Rights to Phase III Netupitant-Palonosetron Fixed Dose Combination for China

The two companies sign a distribution and license agreement for an investigational therapy for the prevention of chemotherapy-induced nausea and...


Dec 11, 2013, 07:59 ET Helsinn Group et Eisai annoncent l'acceptation de la FDA de la mise sur le marché de la combinaison de recherche de netupitant 300 mg + palonosétron 0,50 mg (NEPA)

Recherche d'indication pour la prévention des nausées et vomissements chimio-induits Helsinn Group et Eisai Inc. ont annoncé...


Dec 10, 2013, 04:55 ET Helsinn Group y Eisai anuncian la aceptación de la FDA de una nueva aplicación de fármaco para NEPA

- Helsinn Group y Eisai anuncian la aceptación de la FDA de una nueva aplicación de fármaco para el compuesto en investigación...